144 related articles for article (PubMed ID: 16123676)
1. Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
Lu J; Whitcomb J; Kuritzkes DR
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):20-3. PubMed ID: 16123676
[TBL] [Abstract][Full Text] [Related]
2. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
[TBL] [Abstract][Full Text] [Related]
3. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
4. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
[TBL] [Abstract][Full Text] [Related]
5. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
[TBL] [Abstract][Full Text] [Related]
6. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
[TBL] [Abstract][Full Text] [Related]
7. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
8. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
9. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Radzio J; Yap SH; Tachedjian G; Sluis-Cremer N
AIDS; 2010 Mar; 24(5):659-67. PubMed ID: 20160634
[TBL] [Abstract][Full Text] [Related]
10. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
Harrigan PR; Bloor S; Larder BA
J Virol; 1998 May; 72(5):3773-8. PubMed ID: 9557659
[TBL] [Abstract][Full Text] [Related]
11. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
12. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
[TBL] [Abstract][Full Text] [Related]
14. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
15. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
16. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.
Goudsmit J; De Ronde A; Ho DD; Perelson AS
J Virol; 1996 Aug; 70(8):5662-4. PubMed ID: 8764084
[TBL] [Abstract][Full Text] [Related]
18. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
Kamkamidze G; Sullivan T; Charbonneau T
J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
[TBL] [Abstract][Full Text] [Related]
20. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
